FQHCs and pharmacies press for clearinghouse model to replace 340B claim modifiers; pharma voices concerns

House Bill 3409 A drew a packed public hearing and sharply divided testimony Tuesday as federally qualified health centers, pharmacies and advocates asked the Senate Committee on Health Care to allow a neutral third‑party clearinghouse to determine whether a prescription qualifies for 340B discounts rather than requiring pharmacies to apply a claims modifier.

Proponents told the committee the current modifier‑based approach is administratively burdensome, causes back‑office rework and delays prescriptions at retail counters. They urged the committee to permit covered entities to use a clearinghouse that would match claims data across prescribers, pharmacies and payers so eligibility can be determined at or soon after point‑of‑sale.

Why it matters: Under the currently prevalent practices, pharmacists sometimes must reopen and resubmit claims after learning a drug was 340B‑eligible, administrative work that proponents say is time consuming and error prone. Supporters say a clearinghouse model — used for Medicaid in Oregon — would be faster, reduce pharmacy wait times and produce better, consistent data accessible to manufacturers and PBMs for reconciliation.

Key testimony and arguments - Representative Rob Nosse’s office (Alex Fahlman testified) and Representative Nosse described the bill’s aim as reducing administrative burden and improving transparency through a neutral clearinghouse process used elsewhere in Medicaid systems. - Marty Carty of the Oregon Primary Care Association said the clearinghouse would be a neutral third party and noted the state already uses a clearinghouse (GainWell Technologies) for Medicaid duplicate‑discount prevention; proponents have contracted with private clearinghouses for commercial claims reconciliation. - Marcus Cox, pharmacy director for Klamath Health Partnership, said the modifier process is “burdensome for our pharmacies” and sometimes “close to impossible” for contract pharmacies. - Pharmaceutical Research and Manufacturers of America (PhRMA) and other industry witnesses opposed the bill in written and oral testimony, saying the clearinghouse model is not yet proven in the commercial market, that third‑party intermediaries are already extracting large fees from the program and that state action could undercut federal reforms and best practices. - Patient advocates warned that adding new intermediaries can divert resources away from patient services; one patient advocate noted the program’s original intent was to benefit patients and urged careful consideration before shifting arrangements.

Conflict‑of‑interest and neutrality concerns Proponents told the committee the bill includes conflict‑of‑interest protections so that PBMs could not simultaneously act as the neutral clearinghouse for the same entities. Witnesses cautioned that if a vendor were functionally connected to a PBM, it would undermine neutrality; proponents said a well‑defined wall between business lines can address that concern and indicated the bill’s language disallows clearinghouses that are PBMs.

Data and cost questions Committee members repeatedly asked for clear, quantifiable accounting of how much third‑party vendors and contract pharmacies earn on 340B transactions and how much could shift to clearinghouse vendors. Witnesses representing FQHCs said they could not provide a single statewide percentage but argued that administrative savings and fewer claim resubmissions would be a fraction of total 340B discounts and would free resources for patient care. Industry witnesses pointed to federal reports showing billions in fees to intermediaries and urged caution.

Next steps The committee held robust testimony and did not immediately vote on the measure. Members asked proponents and opponents to confer to clarify conflict‑of‑interest language, data access and the financial flows that would fund a neutral clearinghouse; staff noted that additional paperwork and amendments may follow.

Ending note Supporters described the bill as a technical fix to a time‑consuming process that would mirror Medicaid practice in Oregon; opponents said it risks enabling third‑party intermediaries to extract more program value. The committee kept the record open to reconcile those competing concerns.